TUMOR MARKER "CA15-3" IN BREAST CANCER
Nihon Rinsho Geka Gakkai Zasshi (journal of Japan Surgical Association)(1989)
摘要
The clinical significance of breast cancer-related antigen CA15-3 and its relationship with CEA are examined. Subjects are 328 cases comprising of 90 of primary breast cancer, 28 of relapsed breast cancer, 66 of postoperative and non-relapsed breast cancer, 46 of benign mammary glandular diseases, 59 of other organic cancers, 16 of puerperae and 23 of healthy females. When CA15-3 levels more than 25U/ml were regarded as positive, the positive rate was as low as 13.7% or 33.3% for stage I or stage II cancer respectively, so that CA15-3 might not be a possible candidate for screening marker. However, significant high levels of serum CA15-3 and the positive rate in cases above n1β indicated the usefulness of CA15-3 as an index of biological malignancy. CA15-3-positive was rated as igh as 79.3% for relapsed breast cancer, indicating a favorable feature of CA15-3 as monitoring marker for postoperative relapse. Moreover, well-coincided variation of serum CA15-3 with therapeutic effects in advanced or relapsed cancers revealed that CA15-3 was a valuable index in judging therapeutic efficacy. In terms of relationship between CA15-3 and CEA, correlation coefficient between the both was as low as r=0.287 for relapsed breast cancer, suggesting a greater effectiveness of combination assay with CA15-3 and CEA as postoperative monitoring. CA15-3 appears to be as the same substance as antigen DF3, and immunohistochemical assay revealed that antigen DF3 localized in the cytoplasm of breast cancer cells.
更多查看译文
关键词
breast cancer,marker
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要